-+ 0.00%
-+ 0.00%
-+ 0.00%

FDA GRANTS PRIORITY REVIEW TO INSMED'S SNDA FOR ARIKAYCE® (AMIKACIN LIPOSOME INHALATION SUSPENSION) FOR TREATMENT OF MAC LUNG DISEASE WITH PDUFA TARGET ACTION DATE SET FOR JANUARY 28, 2027

路透·09/21/2026 11:00:00

请登录查看新闻详情